A multicentre, randomised, open-label, parallel-group, phase III post-marketing clinical study to compare the overall survival between gefitinib and docetaxel in patients with advanced or metastatic (stage IIIB/IV), or recurrent non-small cell lung cancer, who have failed one or two chemotherapy regimens

Trial Profile

A multicentre, randomised, open-label, parallel-group, phase III post-marketing clinical study to compare the overall survival between gefitinib and docetaxel in patients with advanced or metastatic (stage IIIB/IV), or recurrent non-small cell lung cancer, who have failed one or two chemotherapy regimens

Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2016

At a glance

  • Drugs Gefitinib (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Sep 2008 Primary endpoint 'overall survival' has not been met.
    • 10 Sep 2008 Results reported in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top